Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)‘s stock had its “equal weight” rating reissued by Morgan Stanley in a report issued on Wednesday. They presently have a $69.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $80.00. Morgan Stanley’s price target would suggest a potential upside of 34.24% from the stock’s current price.

Several other brokerages have also issued reports on RARE. Stifel Nicolaus reaffirmed a “buy” rating and set a $111.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 30th. Canaccord Genuity set a $98.00 price objective on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research report on Friday, July 28th. BidaskClub upgraded Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Jefferies Group LLC raised their target price on Ultragenyx Pharmaceutical from $66.00 to $68.00 and gave the company a “hold” rating in a research note on Monday, May 8th. Finally, ValuEngine upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $74.82.

Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down 0.06% during trading on Wednesday, hitting $51.40. The stock had a trading volume of 385,916 shares. The company’s 50-day moving average is $63.33 and its 200 day moving average is $66.26. The firm’s market cap is $2.18 billion. Ultragenyx Pharmaceutical has a 52 week low of $50.49 and a 52 week high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.73) by $0.01. During the same period last year, the company posted ($1.46) EPS. Equities analysts expect that Ultragenyx Pharmaceutical will post ($7.21) EPS for the current fiscal year.

WARNING: “Morgan Stanley Reaffirms “Equal Weight” Rating for Ultragenyx Pharmaceutical Inc. (RARE)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/24/ultragenyx-pharmaceutical-inc-rare-given-equal-weight-rating-at-morgan-stanley.html.

A number of institutional investors have recently added to or reduced their stakes in RARE. Ameritas Investment Partners Inc. increased its position in Ultragenyx Pharmaceutical by 3.7% in the first quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 115 shares during the last quarter. Prudential Financial Inc. increased its position in shares of Ultragenyx Pharmaceutical by 5.8% in the first quarter. Prudential Financial Inc. now owns 3,660 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 200 shares in the last quarter. Amalgamated Bank increased its position in shares of Ultragenyx Pharmaceutical by 4.6% in the first quarter. Amalgamated Bank now owns 4,628 shares of the biopharmaceutical company’s stock worth $314,000 after buying an additional 202 shares in the last quarter. Tocqueville Asset Management L.P. increased its position in shares of Ultragenyx Pharmaceutical by 8.0% in the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 250 shares in the last quarter. Finally, Aperio Group LLC increased its position in shares of Ultragenyx Pharmaceutical by 8.4% in the second quarter. Aperio Group LLC now owns 3,851 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 299 shares in the last quarter. 95.71% of the stock is owned by institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.